It looks like so but it's up to the experts to give this phenomenon a name. We see during early months (2wks after 1st dosing being most responsive) on avg there was 150% increase in p1np while ctx decreased an avg 50% - signals its dual-action with a net overall effect of bone formation. The second half of the treatment year especially towards the few months in the end, p1np trended towards baseline while ctx remained below baseline - bone markers behaved simikar to an antiresorptive but not exact. This paper analysed evenity's effect based on bone histomorphometry analysis at 2 and 12mo, the authors called it 'bone-forming and antiresorptive effect':
https://pmc.ncbi.nlm.nih.gov/articles/PMC7027577/
Interestingly there is a similarity in the behavior of p1np and CTx when comparing monthly evenity dosing with teriparatide once weekly dosing, seen in the publications by Japanese researchers. Teriparatide wasn't called an antiresorptive in anyway so...